Drug Discovery Featured Articles & Applications

1. iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody 6/25/2026

   iBio has started clinical trials with a long-acting myostatin/GDF11 antibody that can make weight loss healthier and more durable for patients taking GLP-1 agonists.

2. Organizing Digital Systems Around Novel Modalities 6/24/2026

   Cell therapies represent an important advancement in our ability to treat difficult cancers, but continued exploration of this new modality will require new digital tools and equipment.

3. The Future Is Ancient: Evolution, Metabolics, And AI 6/23/2026

   We caught up with Hannah Gordon, Ph.D., chief scientific officer of Enveda, to discuss why the future may depend more on decoding nature’s evolutionarily selected chemistry.

4. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

   The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

5. Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire 6/19/2026

   We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.

6. Aligning Standards, Validation, And Governance For Digital Preclinical Research 6/18/2026

   No single body integrates preclinical data components into a coherent discipline supported by shared standards, common terminology, and collective accountability.

7. How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3) 6/15/2026

   Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.

8. Can Molecular Glue Degraders Make The Undruggable Druggable? 6/12/2026

   Neomorph CEO Phil Chamberlain explains how molecular glue degraders could expand the druggable proteome and why the modality’s small-molecule profile may matter as much as its novel mechanism.

9. 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics 6/12/2026

   Arvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.

10. 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics 6/11/2026

    Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.